Integra LifeSciences reported Q4 2020 revenues of $388.6 million, a decrease of 1.6% compared to Q4 2019. GAAP earnings per diluted share were $1.09, compared to $0.18 in Q4 2019, and adjusted earnings per diluted share were $0.84, compared to $0.68 in Q4 2019.
Reported revenues were $388.6 million, representing a decrease of 1.6% on a reported basis and a decrease of 1.5% on an organic basis compared to the fourth quarter 2019.
Fourth quarter revenues increased 5.0% compared to the third quarter of 2020.
GAAP earnings per diluted share were $1.09, compared to $0.18 in the fourth quarter 2019.
Adjusted earnings per diluted share were $0.84, compared to $0.68 in the fourth quarter of 2019.
For the first quarter 2021, the Company expects reported revenues in the range of $345 million to $355 million, representing reported growth of approximately (3.0%) to 0.0% and organic growth of approximately 0.0% to 3.0%. Adjusted earnings per diluted share are expected to be in a range of $0.54 to $0.58. For the full-year 2021, the Company expects revenues to be in a range of $1,520 million to $1,535 million, representing reported growth of 11% to 12% and organic growth of 12% to 13%. Adjusted earnings per diluted share are expected to be in a range of $2.86 to $2.93.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance